Reverse cholesterol transport pathway in experimental chronic renal failure

American Journal of Nephrology

Volumn 30, Issue 2, 2009, Pages 147-154

  Moradi, Hamid ^a   Yuan, Jun ^a   Ni, Zhemin ^a   Norris, Keith ^b   Vaziri, Nosratola D ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; Lipid disorders; Oxidative stress

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIVER X RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ESTERIFICATION; INFLAMMATION; LIPID OXIDATION; LIPID STORAGE; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UREA BLOOD LEVEL;

ANIMALS; CHOLESTEROL; GENE EXPRESSION REGULATION; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPIDS; LIVER; MACROPHAGES; MALE; MODELS, BIOLOGICAL; NEPHRECTOMY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SCAVENGER;

EID: 62849094523     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210020     Document Type: Article

References (37)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305. (Pubitemid 39268908)
2. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006; 290: 262-272.
3. Gough PJ, Greaves DR, Suzuki H, Hakkinen T, Hiltunen MO, Turunen M, Herttuala SY, Kodama T, Gordon S: Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19: 461-471. (Pubitemid 29135143)
4. Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-228.
5. Genest J Jr, Marcil M, Denis M, Yu L: High density lipoproteins in health and in disease. J Investig Med 1999; 47: 31-42. (Pubitemid 129537255)
6. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-488. (Pubitemid 32323377)
7. Fielding CJ, Fielding PE: Cellular cholesterol efflux. Biochim Biophys Acta 2001; 1533: 175-189.
8. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipo-protein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31. (Pubitemid 29536327)
9. Oram JF, Vaughan AM: ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99: 1031-1043. (Pubitemid 44729927)
10. Neufeld EB, Remaley AT, Demosky SJ Jr, Stonik JA, Cooney AM, Comly M, Dwyer NK, Zhang M, Blanchette-Mackie J, Santamarina-Fojo S, Brewer HB Jr: Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 2001; 276: 27584-27590. (Pubitemid 37410679)
11. Tontonoz P, Mangelsdorf DJ: Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993. (Pubitemid 36683707)
12. Glomset JA: The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-167.
13. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-520. (Pubitemid 26044473)
14. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421: 75-79. (Pubitemid 36077087)
15. Liang K, Kim C, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005; 288:F539-F544. (Pubitemid 40279460)
16. Vaziri ND, Liang K, Parks JS: Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 2001; 59: 2192-2196. (Pubitemid 32467611)
17. Vaziri ND, Sato T, Liang K: Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 2003; 63: 1756-1763.
18. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85.
19. Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992; 41: 1653-1661.
20. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ: Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol 1998; 274: F642-F649. (Pubitemid 28217779)
21. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND: Lead-induced hypertension. Interplay of nitric oxide and reactive oxygen species. Hypertension 1997; 30: 1487-1492.
22. Sweet DH, Miller DS, Pritchard JB: Basolateral localization of organic cation transporter 2 in intact renal proximal tubules. Am J Physiol Renal Physiol 2000; 279:F826-F834. (Pubitemid 30952025)
23. Vaziri ND, Liang K, Park JS: Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 2001; 280:F823-F828. (Pubitemid 32441257)
24. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-1466.
25. Chen M, Masaki T, Sawamura T: LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002; 95: 89-100. (Pubitemid 34895094)
26. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T: Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 275: 12633-12638. (Pubitemid 30241412)
27. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T: The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001; 276: 13750-13755. (Pubitemid 37391749)
28. Moore KJ, Freeman MW: Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006; 26: 1702-1711.
29. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
30. Vaziri ND: Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 2004; 24: 469-473. (Pubitemid 39361056)
31. 1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323: 85-93.
32. Brown MS, Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-340. (Pubitemid 27220877)
33. De Winther M, Hofker M: Scavenging new insights into atherogenesis. J Clin Invest 2000; 105: 1039-1041.
34. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G: Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45. (Pubitemid 41814809)
35. Shao B, Oda MN, Oram JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006; 21: 322-328. (Pubitemid 44315065)
36. Liang K, Vaziri ND: Downregulation of hepatic high-density lipoprotein receptor, SRB1 in nephrotic syndrome. Kidney Int 1999; 56: 621-626.
37. Fabre AC, Vantourout P, Champagne E, Tercé F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO: Cell surface adenylate kinase activity regulates the F (1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 2006; 63: 2829-2837.